Abstract: The use of a compound for preparing a pharmaceutical composition to reduce levels of TNF?, IL-6, and/or IL-1?. The compound can be used to treat immune or metabolic disorders associated with high levels of TNF?, IL-6, IL-1?, or with high levels of ACE-2 and the respective cardiac, renal and blood-pressure-related consequences, including the problems associated with treatments involving antibodies, or cell therapies, or conditions such as hypertension, myocarditis, pericarditis, coagulopathies, thrombotic, cardiovascular or renal events, or type-2 diabetes, and diseases caused by viruses such as influenza or coronavirus. The in-vivo administration of the composition of the invention affects the modulation of cytokine levels in mammals, and said cytokines are related to high levels of ACE-2, have been shown to be correlated with the severity of the disease associated with SARS-CoV-2, and have been identified as indicative markers of the prognosis of the severity thereof.

Abstract: A peptide compound in the fields of pharmaceutical sciences, medicine, chemistry and biotechnology, that shows stability and ease of handling when compared to the more closely related peptidic compounds. A pharmaceutical composition that includes the peptidic compound and shows therapeutic results even when administered orally. In some embodiments, administration of the pharmaceutical composition provides superior therapeutic results when compared to the effects of hemopressin and cannabidiol. In some embodiments, oral administration of the pharmaceutical composition provides neuromodulation, both in the curative or prophylactic treatment of seizures, modulation of pain threshold and important neuroprotection, and reduction of the clinical symptoms of Multiple Sclerosis.

Abstract: The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: the use of a peptide compound for preparing an anticonvulsant pharmaceutical composition; and a therapeutic method. The peptide compound of the claimed pharmaceutical composition binds to and/or modulates the activity of cannabinoid receptors (CB), particularly CB1 and/or CB2, and has proven to be extremely useful as an anticonvulsant. In one embodiment, the claimed pharmaceutical composition provides excellent anticonvulsant results when administered orally to a mammal, and, in addition to other advantages and technical effects, does not entail the drawbacks arising from the use of cannabinoid substances such as cannabidiol, and provides a stronger therapeutic effect in smaller dosages and with fewer side effects.

Abstract: The present invention relates to the fields of chemistry, pharmacy, biotechnology and medicine. More particularly, the present invention describes: the use of a peptide compound for preparing an anticonvulsant pharmaceutical composition; and a therapeutic method. The peptide compound of the claimed pharmaceutical composition binds to and/or modulates the activity of cannabinoid receptors (CB), particularly CB1 and/or CB2, and has proven to be extremely useful as an anticonvulsant. In one embodiment, the claimed pharmaceutical composition provides excellent anticonvulsant results when administered orally to a mammal, and, in addition to other advantages and technical effects, does not entail the drawbacks arising from the use of cannabinoid substances such as cannabidiol, and provides a stronger therapeutic effect in smaller dosages and with fewer side effects.

Abstract: The present invention discloses novel non-natural and modified peptides acting as cannabinoid (CB) receptors ligands, especially CB1 and/or CB2, useful as modulators of its activity; they are also described as a kit and a process in vitro for evaluating the binding to CB receptors, uses and pharmaceutical composition for modulating the CB receptors activity. The invention covers the non-natural peptide of SeqID:1 and those having at least 70% similarity related to the same, including as achievements specialty useful of the invention the non-natural peptides of SeqID:2, SeqID:3, SeqID:4, SeqID:5, SeqID:6.

Abstract: The present invention refers to a pharmaceutical composition that includes an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle. The pharmaceutical composition may be used for the treatment of obesity and the prevention of and the treatment of diabetes.

Abstract: The present invention refers to a pharmaceutical composition that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle. Said pharmaceutical composition may be used for the treatment of obesity and the prevention of and the treatment of diabetes.

Abstract: The present invention discloses novel non-natural and modified peptides acting as cannabinoid (CB) receptors ligands, especially CB1 and/or CB2, useful as modulators of its activity; they are also described as a kit and a process in vitro for evaluating the binding to CB receptors, uses and pharmaceutical composition for modulating the CB receptors activity. The invention covers the non-natural peptide of SeqID:1 and those having at least 70% similarity related to the same, including as achievements specialty useful of the invention the non-natural peptides of SeqID:2, SeqID:3, SeqID:4, SeqID:5, SeqID:6.

Abstract: The present invention refers to a pharmaceutical compositions that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle.